Browse the evidence

Metabolic surgery, intensive lifestyle modification, and pharmacologic approaches are viable options for achieving diabetes remission.

Practitioners should consider these options early in the disease course for better outcomes.

Comprehensive management of diabetic nephropathy includes lifestyle interventions and medication selection.

Practitioners should implement lifestyle changes alongside medication for effective management.

Canagliflozin results in weight loss and reduction of blood pressure.

Incorporating canagliflozin may aid in weight management and blood pressure control for diabetic patients.

The management of MASLD in patients with T2D includes dietary and behavioral management, pharmacological treatment, and bariatric procedures.

Practitioners should consider a comprehensive management approach for diabetic patients with MASLD.

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) decreased from 82.6% to 30.4% after treatment with semaglutide.

Semaglutide may significantly improve liver health in patients with type 1 diabetes and MASLD.

Lifestyle intervention combined with older obesity medications is associated with approximately 5%-10% weight loss.

Combining lifestyle changes with medications can enhance weight loss outcomes for patients.

GLP-1 analogs have shown efficacy in improving weight loss and cardiovascular risk factors.

Practitioners may consider GLP-1 analogs as a treatment option for weight management in menopausal women.

Lifestyle modification can provide glycemic benefits to prevent type 2 diabetes (T2D) and its comorbidities.

Practitioners should encourage lifestyle modifications as a standard approach to prevent T2D.

Soy isoflavones can significantly contribute to lowering metabolic risk and affect hormonal balance in women with PCOS.

Incorporating soy isoflavones may be beneficial for women with PCOS in managing metabolic and hormonal issues.

The intervention resulted in a decrease in body weight, body mass index, waist circumference, blood pressure, and lipid metabolism parameters.

Health professionals can expect improvements in key health metrics when implementing similar interventions.

GLP-1RAs promote weight loss and improve metabolic health.

GLP-1RAs can be utilized to aid in weight management and metabolic health improvement.

The combination of Cinnamomum cassia (300 mg) and Withania somnifera (150 mg) induced significant weight loss compared to placebo (−2.66% vs. −1.28%, respectively; p = 0.0002).

Practitioners may consider this combination as a low-cost supplement option for enhancing weight loss in overweight and obese patients.

Obesity is associated with serious health risks and consequences for individuals who are pregnant or want to be pregnant.

Healthcare providers should be aware of the risks obesity poses to pregnant individuals.

Lifestyle interventions, such as adherence to a Mediterranean diet and weight loss, have proven beneficial for both metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure with preserved ejection fraction (HFpEF).

Encouraging patients to adopt a Mediterranean diet and focus on weight loss can be beneficial for managing both MASLD and HFpEF.

Obesity is a major contributor to type 2 diabetes, necessitating medication management for both conditions.

Addressing obesity is crucial in managing type 2 diabetes, and medication may be necessary.

Bariatric interventions have shown the best therapeutic benefits in individuals with obesity.

Bariatric interventions should be considered as a primary treatment option for obesity.

Exenatide combined with Metformin significantly reduced insulin resistance (HOMA-IR) by a mean difference of -0.9 (p < 0.001).

Practitioners may consider the combination of Exenatide and Metformin as an effective treatment for improving insulin resistance in women with PCOS.

Exenatide combined with Metformin reduced body mass index (BMI) by a mean difference of -0.4 (p = 0.03).

The combination therapy may assist in weight management for women with PCOS.

All secondary cardiometabolic outcomes improved significantly throughout the study.

Practitioners can consider compounded GLP-1 ± GIP agonists as effective for improving various cardiometabolic risk factors.

Intensive lifestyle modification and medications that improve insulin resistance are key strategies for preventing type 2 diabetes (T2D).

Practitioners should focus on lifestyle changes and medications to prevent T2D.

Lifestyle measures such as increasing physical activity and improving diet are considered the basis of any drug therapy for dyslipidemias.

Practitioners should prioritize lifestyle interventions in managing dyslipidemias.

Meal replacements (MRs) lead to a significant reduction in fasting blood sugar (FBS) by 3.10 mg/dL.

Incorporating meal replacements can effectively lower fasting blood sugar levels.

The new glycemia targeted specialized supplement (GTSS) produced a 25% reduction in the incremental area under the curve (iAUC) of postprandial blood glucose (PPG) compared to a standardized breakfast.

Using GTSS as a breakfast replacement may help lower postprandial blood glucose levels in patients with type 2 diabetes.

Chronic data generally indicate that supersets and traditional resistance training lead to similar adaptations for endurance, hypertrophy, power, and strength.

Both training modalities can be used interchangeably for long-term adaptations.